FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini(University of Pisa), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Gabriella Fontanini(University of Pisa), Elisa Sensi(University of Pisa), Silvia Mezi(Policlinico Umberto I), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Mauro D’Amico(Ente Ospedaliero Ospedali Galliera), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Sara Lonardi(Istituto Oncologico Veneto), Cristiana Lupi(University of Pisa), Fotios Loupakis(Azienda Ospedaliera Universitaria Pisana), Giuseppe Tonini(Campus Bio Medico University Hospital), Chiara Carlomagno(Federico II University Hospital), Carlotta Antoniotti(University of Pisa), Luca Boni(Ospedale Policlinico San Martino), Cristina Granetto, Giacomo Allegrini, Gianluca Tomasello(Istituti Ospitalieri di Cremona), Silvana Chiara(Ospedale Policlinico San Martino), Monica Ronzoni
Cited by 1,092
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k